Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Association of Previous Vedolizumab Treatment and Fibroblast-Derived MMP13 with Nonresponse to Ustekinumab in Ulcerative Colitis Patients

  • By

  • Yuiko Tsuruta

  • Yoki Furuta

  • Masatoshi Nakashima

  • Cheng Pan

  • Shota Takano

  • Koichi Sakurai

  • Hideki Kitada

  • Kana Omoto

  • Taichi Matsuyama

  • Yoshinari Sakai

  • Suguru Chiyonaga

  • Kotaro Fukubayashi

  • Takashi Shono

  • Masakuni Tateyama

  • Kotaro Waki

  • Munenori Honda

  • Kenshi Matsuno

  • Akira Yamasaki

  • Hideaki Miyamoto

  • Ryosuke Gushima

  • Takehisa Watanabe

  • Katsuya Nagaoka

  • Hideaki Naoe

  • Yoshihiro Komohara

  • Yasuhito Tanaka

  • September 28, 2026

Share

Original Source(s)

Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis

  • by Yuiko Tsuruta, Yoki Furuta, Masatoshi Nakashima, Cheng Pan, Shota Takano, Koichi Sakurai, Hideki Kitada, Kana Omoto, Taichi Matsuyama, Yoshinari Sakai, Suguru Chiyonaga, Kotaro Fukubayashi, Takashi Shono, Masakuni Tateyama, Kotaro Waki, Munenori Honda, Kenshi Matsuno, Akira Yamasaki, Hideaki Miyamoto, Ryosuke Gushima, Takehisa Watanabe, Katsuya Nagaoka, Hideaki Naoe, Yoshihiro Komohara, Yasuhito Tanaka

  • September 28, 2026

Related Content

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis

Damage control surgery and open abdomen in Hinchey III–IV acute diverticulitis: current practice from a nationwide Italian survey

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy